1
项与 程序死亡受体1敲减的靶向CD269嵌合抗原受体工程化T细胞 (上海优卡迪) 相关的临床试验A Phase 3, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of Clarithromycin(Biaxin)-Lenalidomide-Low-Dose-Dexamethasone (BiRd) Combined With B-cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-cell Therapy in Patients With Newly Diagnosed Multiple Myeloma
The purpose of this study is to evaluate the safety and efficacy of BiRd regimen combined with BCMA CAR T cell therapy in newly diagnosed multiple myeloma patients
100 项与 程序死亡受体1敲减的靶向CD269嵌合抗原受体工程化T细胞 (上海优卡迪) 相关的临床结果
100 项与 程序死亡受体1敲减的靶向CD269嵌合抗原受体工程化T细胞 (上海优卡迪) 相关的转化医学
100 项与 程序死亡受体1敲减的靶向CD269嵌合抗原受体工程化T细胞 (上海优卡迪) 相关的专利(医药)
100 项与 程序死亡受体1敲减的靶向CD269嵌合抗原受体工程化T细胞 (上海优卡迪) 相关的药物交易